| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787638 | Journal of Thoracic Oncology | 2018 | 24 Pages |
Abstract
These findings do not support further evaluation of nivolumab 240 mg every 2 weeks plus crizotinib 250 mg twice daily.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
David R. MD, Craig MD, David MD, Edward B. MD, Jason MD, Sunil MD, Paul MD, Alexander MD, Robert MD, Jin MD, Wen Hong MD, George MD,